Released on = March 29, 2006, 12:42 am

Press Release Author = Bio3 Research

Industry = Biotech

Press Release Summary = Bio3 Research s.r.l. and Daxley Group S.A. today announced
that they have entered into an agreement granting Daxley Group a license to develop,
produce and market Bio3 Research's cysteine-based product BiocysanT in Latin America
for oral use in dialyzed patients.

Press Release Body = Milan, Italy and Montevideo, Uruguay (OPENPRESS) March 29, 2006
-- Bio3 Research s.r.l. and Daxley Group S.A. today announced that they have entered
into an agreement granting Daxley Group a license to develop, produce and market
Bio3 Research's cysteine-based product BiocysanT in Latin America for oral use in
dialyzed patients.

Bio3 Research owns patent applications covering the composition and oral use of
cysteine alone and in combination with other molecules for end-stage renal disease
(ESRD). BiocysanT is expected to reduce the risk of anemia in ESRD patients by
increasing the shortened half-life of erythrocytes. ESRD patients frequently become
severely anemic when oxidative stress during hemodialysis causes diminished levels
of glutathione, an antioxidant, in their blood.

Daxley Group will soon start clinical studies in Mexico to confirm that BiocysanT
improves the most important parameters involved in severe anemia in hemodialyzed
patients.

Francesco Paolo Pilato, President and CEO of Bio3 Research, said, "We are delighted
to have entered into this agreement with Daxley Group. We believe this is a great
opportunity for our company to confirm the key role of oral cysteine in preventing
severe anemia in hemodialysis patients."

"Daxley Group is excited about its collaboration with Bio3 Research," said Arnaldo
A. Massone, Daxley Group's Chairman and CEO. "This agreement will enable us to
develop and market a product that is supported by strong IP and has great potential
to help large numbers of dialyzed patients."

About Daxley Group S.A.
Daxley Group S.A. is a privately owned drug development and marketing company,
founded in 2003. Based in Montevideo, Daxley Group has affiliates throughout Latin
America. The group's activity focuses mainly on highly specialized products in the
areas of infertility, gynecology, neurology, cardiology, nephrology andnutrition.

About Bio3 Research s.r.l.
Bio3 Research s.r.l., an Italian company founded in 2001, has headquarters in Milan
and an office at the Bioindustry Park of Canavese (Turin). Bio3 Research works with
research institutions, individual scientists and early-stage companies to identify,
protect and exploit commercially promising intellectual property in the life
sciences. Such assistance may include pre-clinical development and negotiation of
strategic industrial partnerships. Bio3 Research's activity focuses mainly on the
field of HMBG1-related cardiovascular disorders and use of HMGB1 and its fragments
in connective tissue regeneration. Other fields of interest include skin and renal
diseases. Additional information on Bio3 Research can be obtained from
www.bio3research.com or by e-mail: info@bio3research.com

Web Site = http://www.bio3research.com

Contact Details = Via della Moscova6/8
20121 Milano
Italy